Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ImmunoCellular Therapeutics Ltd
IMUC | US
0.13
USD0
0%
IMUC | US
Loading StockChartView...
About ImmunoCellular Therapeutics Ltd
Sector
Healthcare
Industry
Biotechnology
Earnings date
31/12/2022
As of date
09/03/2026
Close
0.13
Open
0.12
High
0.18
Low
0.12
Immunocellular Therapeutics Ltd. a clinical-stage pharmaceutical company focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147 an investigational broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics Ltd. was founded in 2020 and is headquartered in Montvale New Jersey.
View LessIMUC | US
Risk
748.2
Sharpe
-0.01
Luna's Score
37/100
Recommendation
Sell
Luna says (IMUC | US)
What's Working
Low Debt to Equity (< 0.25)
Value Stock (Price to Book < 3)
What's not Working
Negative Momentum (Declining Price)
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
922.1%1 month
748.2%3 months
746.0%6 months
723.0%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
0.02
Fwd. PE
-
Price to book
0.35
Debt to equity
-0.83
Debt to assets
4.51
Ent. to EBITDA
-3.81
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-6.07M
MarketCap
14.85M
MarketCap(USD)
14.85M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-2.31K
Short ratio
4.13
Short perc.
3.96
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
0.10
Range1M
0.11
Range3M
0.15
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
1.37
Price X volume
505.40
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -3.81 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | 0.02 | 41.03 | Cheaper |
| Price to Book | 0.35 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 746.04 | 72.80 | Riskier |
| Debt to Equity | -0.83 | -1.23 | Expensive |
| Debt to Assets | 4.51 | 0.25 | Expensive |
| Market Cap | 14.85M | 3.66B | Emerging |
